PACB — Pacific Biosciences of California, Inc. stock price, charts and financials

QT33Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
1.44
+0.02+1.41%
PACBQT33Pacific Biosciences of California, Inc.·NASDAQ
1.44+1.41%
News
Up 1.4% — What's in Store for These 4 Healthcare Companies This Earnings Season? (zacks.com).
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.43Insider Own6.73%Shs Outstand310.60MPerf Week3.60%
Market Cap447.27MForward P/E-EPS next Y-0.47Insider Trans-3.91%Shs Float303.83MPerf Month-13.25%
Enterprise Value874.27MPEG-EPS next Q-0.13Inst Own-Short Float15.22%Perf Quarter-7.10%
Income-128.00MP/S2.80EPS this Y2.79%Inst Trans-Short Ratio7.48Perf Half Y-30.10%
Sales160.00MP/B-EPS next Y-11.96%ROA-16.43%Short Interest46.24MPerf YTD-22.99%
Book/sh0.01P/C1.62EPS next 5Y-ROE-488.45%52W High2.73 -47.25%Perf Year8.27%
Cash/sh0.89P/FCF-EPS past 3/5Y-ROIC-22.69%52W Low1.09 32.11%Perf 3Y-89.33%
Dividend Est.-EV/EBITDA-Sales past 3/5Y7.72% 15.16%Gross Margin37.08%Volatility5.50% 5.98%Perf 5Y-95.20%
Dividend TTM-EV/Sales5.46EPS Y/Y TTM59.81%Oper. Margin-101.72%ATR (14)0.09Perf 10Y-81.68%
Dividend Ex-Date-Quick Ratio4.87Sales Y/Y TTM3.90%Profit Margin-80.34%RSI (14)49.31Recom2.56
Dividend Gr. 3/5Y-Current Ratio5.65EPS Q/Q80.00%SMA20-0.38%Beta2.31Target Price1.00
Payout0.00%Debt/Eq151.80Sales Q/Q0.00%SMA50-1.40%Rel Volume1.03Prev Close1.42
Employees485LT Debt/Eq151.80EarningsNov 03SMA200-15.58%Avg Volume6.24MPrice1.44
IPO DateOct 27, 2010Option/ShortNo / YesEPS/Sales Surpr.78.82% -6.92%Net Debt/EBITDA-6.07Volume6,394,505Change1.41%
Analyst Ratings
DateActionAnalystRatingTarget
Apr-14-26ReiteratedBarclaysUnderweight$1.50$1.00
Mar-06-26DowngradeBarclaysEqual WeightUnderweight
Aug-08-25ReiteratedBernsteinOutperform$1.50$1.70
Jun-25-25ReiteratedBarclaysEqual Weight$2.00$1.50
Nov-11-24DowngradeUBSBuyNeutral
Jun-03-24ReiteratedJefferies$4.00
May-13-24ReiteratedPiper SandlerNeutral$2.00
May-10-24ReiteratedBarclaysEqual Weight$2.00
Apr-22-24DowngradeJP MorganOverweightNeutral
Apr-18-24DowngradeGoldman SachsBuyNeutral$2.50
Latest News
Aug-04-26
Jul-30-26
Jul-28-26
Jul-21-26
Jul-20-26
Jul-15-26
Jul-13-26
Jul-09-26
Jul-07-26
Jul-06-26
Jun-30-26
Company

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue160160154201128131799179
Cost of Goods Sold Incl. D&A1001091171487972465654
Gross Profit605137534959333525
Selling, General and Administrative Excl. Other132141175170161124737563
Research and Development8997135187193113646063
Other Operating Expense237020230232000
Operating Income-163-558-474-334-307-210-104-101-101
Interest Expense4713141513032
Unusual Expense
Non-Operating Income (Expense)3918178318-52134191
Net Income Before Taxes-128-546-310-318-314-27529-84-103
Income Taxes000-110-94001
Consolidated Net Income-128-546-310-307-314-18129-84-103
Net Income From Continuing Operations-128-546-310-307-314-18129-84-103
Net Income-128-546-310-307-314-18129-84-103
EPS (Recurring)-0.43-1.82-1.13-1.21-1.40-0.890.18-0.51-0.76
EPS (Basic, Before Extraordinaries)-0.43-1.82-1.13-1.21-1.40-0.890.18-0.51-0.76
EPS (Diluted)-0.43-1.82-1.07-1.21-1.40-0.890.17-0.51-0.76
EBITDA-107-34-243-271-282-25139-72-93
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio152.59
Price To Sales Ratio2.753.513.2612.4014.3831.8654.188.6412.65
Gross Margin37.5031.8724.0326.3738.2845.0441.7738.4631.65
Operating Margin-101.88-348.75-307.79-166.17-239.84-160.31-131.65-110.99-127.85
Net Margin-80.00-341.25-201.30-152.74-245.31-138.1736.71-92.31-130.38
Shares Outstanding306300274254225204165153135
Market Capitalization4415615012,4921,8414,1744,280786999
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$2.93$2.36$1.79$1.22$0.65 Close Price0.00M0.28M0.56M0.84M1.13MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Gibson James R IISee RemarksApr 01 '26Sale1.3788,185120,8131,245,663Apr 03
HENRY CHRISTIAN OSee RemarksMar 03 '26Sale1.5112,49718,9203,581,813Mar 04
Van Oene MarkSee RemarksMar 03 '26Sale1.516,5049,8472,243,634Mar 04
Farmer MicheleSee RemarksMar 03 '26Sale1.512,9794,510305,948Mar 04
HENRY CHRISTIAN OSee RemarksFeb 18 '26Sale1.63140,874229,4842,673,500Feb 19
Farmer MicheleSee RemarksFeb 18 '26Sale1.6314,95224,357219,092Feb 19
Van Oene MarkSee RemarksFeb 18 '26Sale1.6355,10789,7691,742,638Feb 19
Farmer MicheleSee RemarksFeb 17 '26Sale1.5835,21555,499234,044Feb 19
Van Oene MarkSee RemarksFeb 17 '26Sale1.58129,790204,5491,797,745Feb 19
HENRY CHRISTIAN OSee RemarksFeb 17 '26Sale1.58331,793522,9062,814,374Feb 19
Van Oene MarkSee RemarksAug 18 '25Sale1.3126,83635,1821,920,035Aug 20
Farmer MicheleSee RemarksMay 19 '25Sale1.005,1955,200269,259May 21
HENRY CHRISTIAN OSee RemarksMar 03 '25Sale1.4112,49717,5832,225,357Mar 05
Van Oene MarkSee RemarksMar 03 '25Sale1.416,4869,1261,497,695Mar 05
Farmer MicheleSee RemarksMar 03 '25Sale1.412,9734,183184,619Mar 05
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.